Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 7/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL966799 | 0.98 | KRAS (0.39) | KRASRAPGEF4SCN4ADPP4P2RX7 | |
| SCHEMBL15129221 | 0.85 | KRAS (0.33) | KRASRAPGEF4SCN4ADPP4ALDH1A1 | |
| SCHEMBL2090996 | 0.83 | ALDH1A1 (0.45) | KRASDPP4ALDH1A1DPP8AHR | |
| SCHEMBL12618460 | 0.83 | KRAS (0.53) | KRASRAPGEF4SCN4AP2RX7 | |
| SCHEMBL26566694 | 0.82 | TSHR (0.38) | RAPGEF4ALDH1A1CD44 | |
| SCHEMBL10144197 | 0.80 | CYP3A4 (0.45) | KRASSCN4ADPP4ALDH1A1CD44 | |
| SCHEMBL10051058 | 0.79 | RAPGEF4 (0.41) | KRASRAPGEF4SCN4AP2RX7ALDH1A1 | |
| SCHEMBL14932492 | 0.79 | RAPGEF4 (0.41) | KRASRAPGEF4SCN4AP2RX7ALDH1A1 | |
| SCHEMBL5952499 | 0.78 | SCN4A (0.37) | KRASSCN4ADPP4 | |
| SCHEMBL6151899 | 0.77 | RAPGEF4 (0.39) | KRASRAPGEF4P2RX7ALDH1A1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| EP-1610779-B1 | 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | claimed |
| EP-1869038-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-07-08 | — | — | EP | claimed |
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | claimed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3609868-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | disclosed |
| EP-0934257-A1 | SUBSTITUTED N-ARYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0927034-A1 | METHOD OF TREATING URINARY INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-07-07 | — | — | EP | disclosed |
| US-5763474-A | SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1998011888-A1 | METHOD OF TREATING URINARY INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-26 | — | — | WO | disclosed |
| WO-1998002413-A1 | SUBSTITUTED N-ARYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | KRAS 4202/4885RAPGEF4 4453/4885SCN4A 736/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | KRAS 2652/4885RAPGEF4 2643/4885SCN4A 99/4885 |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | KRAS 3701/4885RAPGEF4 2766/4885SCN4A 1377/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | KRAS 2652/4885RAPGEF4 2643/4885SCN4A 99/4885 |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | KRAS 1194/4885RAPGEF4 1193/4885SCN4A 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.